EMA Idefirix coverage for business development, investment, and market access teams
SERB Pharma has announced its acquisition of European and MENA rights to Idefirix from Hansa. This move is set to impact the competitive landscape significantly.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
